BeiGene touts 'en­cour­ag­ing' re­sponse rates as the Chi­nese biotech mounts chal­lenge to BTK, PD-1 lead­ers

As BeiGene sets the stage for a piv­otal show­down with the OG BTK in­hibitor Im­bru­vi­ca, it’s ze­ro­ing in on a sub­set of pa­tients for whom their drug, zanubru­ti­nib, could be es­pe­cial­ly help­ful.

The biotech — which has ori­gins in Chi­na — al­so bran­dished the lat­est piv­otal re­sults for its PD-1 drug tislelizum­ab, an­oth­er fran­chise shak­er that’s un­der pri­or­i­ty re­view in Chi­na, at the EHA Con­gress.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.